Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Molecular and Cellular Biology|November 17, 2005
Dual regulation of c-Myc by p300 via acetylation-dependent control of Myc protein turnover and coactivation of Myc-induced transcriptionFrancesco Faiola, Xiaohui Liu, Szuying Lo, et al.
Research Square|July 10, 2026
Multi-state modeling associates proliferation genes with early estrogen receptor-positive breast cancer recurrence and survivalYongzhe Wang, Christine Quinones, Irene Kang, et al.
Nature Communications|May 3, 2019
Inhibition of MYC by the SMARCB1 tumor suppressorApril M Weissmiller, Jing Wang, Shelly L Lorey, et al.
Cancer Letters|December 22, 2019
HOTAIRM1 lncRNA is downregulated in clear cell renal cell carcinoma and inhibits the hypoxia pathwayMichael J Hamilton, Matthew Young, Kay Jang, et al.
Plos Pathogens|February 5, 2016
BS69/ZMYND11 C-Terminal Domains Bind and Inhibit EBNA2Matthew R Harter, Cheng-Der Liu, Chih-Lung Shen, et al.
Virology|February 21, 2018
The human T-cell leukemia virus type-1 p30<sup>II</sup> protein activates p53 and induces the TIGAR and suppresses oncogene-induced oxidative stress during viral carcinogenesisMegan Romeo, Tetiana Hutchison, Aditi Malu, et al.
Virology|January 9, 2015
Acetylation of the c-MYC oncoprotein is required for cooperation with the HTLV-1 p30(II) accessory protein and the induction of oncogenic cellular transformation by p30(II)/c-MYCMegan M Romeo, Bookyung Ko, Janice Kim, et al.
Frontiers in Cardiovascular Medicine|May 5, 2022
Impact of Federal, State, and Local Housing Policies on Disparities in Cardiovascular Disease in Black/African American Men and Women: From Policy to Pathways to BiologyChristopher Sistrunk, Nora Tolbert, Maria Dulfary Sanchez-Pino, et al.
Genes & Development|October 18, 2023
MYC acetylated lysine residues drive oncogenic cell transformation and regulate select genetic programs for cell adhesion-independent growth and survivalMatthew Hurd, Jeffrey Pino, Kay Jang, et al.
Cancers|March 28, 2025
Mixed-Methods Approach: Impact of Clinical Consenter Diversity on Clinical Trials EnrollmentAngelica Sanchez, Christina M Vidal, Noé Rubén Chávez, et al.
Pageof 4